Research sheds new light on the behavior of KRAS gene in pancreatic and colorectal cancer

Recent research from the University of Helsinki sheds new light on the behavior of the KRAS gene in two of the deadliest cancers—pancreatic and colorectal cancer.

Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders | Psychedelic Invest

VANCOUVER, BC, Jan. 31, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today

January 31, 2024

Natural Medicine Advisory Bulletin #4: September 2023 – Psychedelic Alpha

*** One new non-voting participant was introduced in the September meeting of the Qualifications, Licensing, and Training subcommittee. The new participant, Luke Priel, is a

November 1, 2023

Ventyx axes development of TYK2 inhibitor following Phase 2 failure

Ventyx Biosciences is shelving a drug after a mid-stage miss and failure. The company was investigating VTX958, an allosteric TYK2 inhibitor, in patients with moderately

July 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.